CEO Transition Process Announcement | CleopatraRX

CEO Transition Process AnnouncementBlaise Staab2025-05-07T22:51:42+00:00

CleopatraRX™ Announces CEO Transition Process to Support Continued Growth and National Momentum

May 2, 2025

CleopatraRX™, a healthcare company focused on advancing cognitive and neurological health for women, is pleased to announce that it has initiated a Chief Executive Officer (CEO) transition plan. Effective as of April 30, 2025, Dina Leeds will no longer serve as CEO. The decision to initiate the search was made unanimously by the Board of Managers (the “Board”), driven by the company’s growth trajectory and the strategic leadership needed to capitalize on its current momentum. The CleopatraRX™ Board has formed a CEO Search Committee to identify a successor. Day-to-day operations will be managed by the existing leadership team to ensure continuity and continued progress across key initiatives.

“As CleopatraRX™ continues to gain national visibility and commercial traction, the Board determined that now is the right time to bring in a new CEO to lead the company through its next stage of growth,” said Kevin Murray, CFO of CleopatraRX and member of the Board. “Recent features on The Today Show, The New York Times, and Oprah have accelerated awareness of CleopatraRX™’s mission, and we are committed to identifying a leader who can scale our business, expand market access, and build lasting value.”

The CEO Search Committee will begin its work immediately and will seek candidates with strong operational, marketing, and fundraising experience, and a demonstrated commitment to advancing innovation in healthcare, particularly in women’s health. “CleopatraRX™ is well positioned, with a differentiated product and a strong customer response,” added Mr. Murray.

Back to Press Room

© Copyright 2025 CleopatraRX™. All Rights Reserved. View our Privacy Policy. and Terms and Conditions.

*PearlPAK™️ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and is used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product for use as a drug/routine system and/or treatment.

The PearlPAK™️ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post-menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.

*PearlPAK™ dose system is not intended to treat neurological diseases including dementia and Alzheimer’s Disease. It is specifically designed to target cognitive difficulties in perimenopause and early menopausal women only. If you are concerned about neurological disease or have a family history of neurological disease, contact your physician.

CleopatraRX™ and PearlPAK™ are trademarks of CleopatraRX Development, LLC. CleopatraRX™ is a service mark and used throughout this website to represent the services offered by CleopatraRX Development, LLC. PearlPAK™ is a dosage product is for use as a drug/routine system and/or treatment.

The PearlPAK™ drug/routine system is protected by U.S. Patent No. 10,369,158 – PHARMACEUTICAL PACKAGING FOR ESTRIOL THERAPY – which relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.

Estriol Therapy U.S. Patent No. 9,962,395 – COMPOSITIONS AND METHODS FOR MAINTAINING COGNITIVE FUNCTION – Provides methods for reducing the progression of cognitive decline in a post – menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.